An Inquiry Into the ImClone Cancer-Drug Story: Hearings Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, Second Session, June 13 and October 10, 2002, Volume 4
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
U.S. Government Printing Office, 2002 - Medical - 759 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
antibody application Audit Committee Board of Directors Bristol Bristol-Myers Squibb cancer patients Cetuximab Chairman Tauzin clinical trials colon cancer colorectal cancer common stock Company Company's Compensation Corporation counsel Crawford December 27 December 31 DeGette disease documents dose employees Erbitux Executive Officer exercisable options exercise Fast Track FDA's Fletcher Goldhammer granted Greenwood Harlan Waksal ImClone stock ImClone Systems Incorporated ImClone's Incentive Stock Option insider trading investigation irinotecan issues January John Mendelsohn Keegan Kopperl loans Markison meeting Mendelsohn million number of shares Okay oncology person prior protocol proxy proxy card purchase pursuant question received refusal to file SAMUEL WAKSAL securities shareholders shares of common shares of ImClone Smaldone statement Stearns stock options stockholders Stupak Thank therapy Tippee transaction treatment tumor Vaczy Vice President vote Weiss York